Vivo Capital’s Monopar Therapeutics MNPR Stock Holding History
Bought
Maintained
Sold
Other funds holding MNPR
SVCM
SL
Vivo Capital's MNPR Position: Q3 2026 in Review
Vivo Capital held its Monopar Therapeutics (MNPR) position steady in Q3 2026 at 90,500 shares worth $7.21M. The position accounts for 0.79% of the portfolio, ranked #33.
Vivo Capital first reported a position in MNPR in Q3 2025 and has held it in 5 quarters since. The position peaked at $8.38M in Q2 2026. 104 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.
- Vivo Capital held 90,500 shares of Monopar Therapeutics worth $7.21M as of Q3 2026.
- Vivo Capital left its Monopar Therapeutics share count unchanged in Q3 2026.
- Monopar Therapeutics made up 0.79% of Vivo Capital's portfolio in Q3 2026, its #33 holding.
- Vivo Capital first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 5 quarters since.
- Vivo Capital's Monopar Therapeutics position peaked at $8.38M in Q2 2026.
- 104 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.
Based on Vivo Capital's 13F filing for Q3 2026, filed 13 Nov 2026.